Literature DB >> 31900480

Exclusion of patients with brain metastases from cancer clinical trials.

Roshal R Patel1,2, Vivek Verma1, Austin B Miller1,3, Timothy A Lin4, Amit Jethanandani5, Andres F Espinoza6, Walker Mainwaring6, Alexander Augustyn1, C David Fuller1, Erik P Sulman7, Debra N Yeboa1, Caroline C Chung1, Mary Frances McAleer1, Jing Li1, Daniel Yoshor6, John F de Groot1, Jacob J Mandel6, Ethan B Ludmir1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 31900480      PMCID： PMC7158639          DOI： 10.1093/neuonc/noz246

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  3 in total

Review 1.  Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Authors:  D Ross Camidge; Eudocia Q Lee; Nancy U Lin; Kim Margolin; Manmeet S Ahluwalia; Martin Bendszus; Susan M Chang; Janet Dancey; Elisabeth G E de Vries; Gordon J Harris; F Stephen Hodi; Andrew B Lassman; David R Macdonald; David M Peereboom; David Schiff; Ricardo Soffietti; Martin J van den Bent; Jeffrey S Wefel; Patrick Y Wen
Journal:  Lancet Oncol       Date:  2018-01       Impact factor: 41.316

2.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.

Authors:  Nancy U Lin; Tatiana Prowell; Antoinette R Tan; Marina Kozak; Oliver Rosen; Laleh Amiri-Kordestani; Julia White; Joohee Sul; Louise Perkins; Katherine Beal; Richard Gaynor; Edward S Kim
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

3.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Authors:  Daniel N Cagney; Allison M Martin; Paul J Catalano; Amanda J Redig; Nancy U Lin; Eudocia Q Lee; Patrick Y Wen; Ian F Dunn; Wenya Linda Bi; Stephanie E Weiss; Daphne A Haas-Kogan; Brian M Alexander; Ayal A Aizer
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300
  3 in total
  4 in total

1.  Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.

Authors:  Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Ashlyn Everett; Drexell H Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; Yi An; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2020-09-15       Impact factor: 44.544

Review 2.  Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases.

Authors:  Ilana Schlam; Margaret E Gatti-Mays
Journal:  Oncologist       Date:  2022-07-05       Impact factor: 5.837

Review 3.  Multidisciplinary Management of Brain Metastases from Non-Small Cell Lung Cancer in the Era of Immunotherapy.

Authors:  Lisa Sudmeier; Sibo Tian; Kristin A Higgins
Journal:  Curr Treat Options Oncol       Date:  2021-07-02

Review 4.  Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases.

Authors:  Aaron C Tan; Drexell H Boggs; Eudocia Q Lee; Michelle M Kim; Minesh P Mehta; Mustafa Khasraw
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.